Your session is about to expire
← Back to Search
Diuretic
Diuretics for Early Chronic Kidney Disease (DOCK Trial)
Phase 4
Recruiting
Led By Lucile P Gregg, MD
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Must not have
Unable to understand or provide informed consent.
CKD stages 4-5, defined as eGFR <30 mL/min/1.73 m2.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks
Awards & highlights
No Placebo-Only Group
Pivotal Trial
Drug Has Already Been Approved
Summary
This trial is testing whether medications that help remove extra fluid from the body can improve heart health in Veterans with early-stage kidney disease and high blood pressure. By reducing fluid volume, these medications may lower blood pressure and decrease heart strain. These medications have been used to manage extra fluid buildup and control blood pressure in various conditions, including heart failure and high blood pressure, for many years.
Who is the study for?
This trial is for Veterans with early-stage chronic kidney disease (CKD stages 1-3) who have high blood pressure. Participants must be at least 18 years old, able to give informed consent, and not on dialysis or a recipient of a kidney transplant. Those with severe heart issues, liver cirrhosis, major limb amputation, pregnancy, or certain devices like pacemakers are excluded.
What is being tested?
The study tests whether diuretics (like hydrochlorothiazide or furosemide) can reduce fluid overload in the body and improve cardiovascular health in people with early CKD. It compares two methods of measuring fluid overload and observes changes in symptoms and short-term heart function after treatment.
What are the potential side effects?
Diuretics may cause dehydration, electrolyte imbalances (like low potassium), dizziness upon standing up due to lowered blood pressure, increased urination frequency, fatigue, muscle cramps or weakness.
Eligibility Criteria
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am able to understand and give informed consent.
Select...
My kidney function is very low (stage 4-5 CKD).
Select...
I have been diagnosed with liver cirrhosis.
Select...
I am willing and able to follow the study's requirements.
Select...
I have received a kidney transplant.
Select...
I am on long-term dialysis treatment.
Select...
I have had a major limb amputation.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 4 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in NT-pro-BNP
Secondary study objectives
Change in BNP
Change in FACIT-F score
Change in KDQOL
+8 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Diuretic augmentationExperimental Treatment1 Intervention
The participant's blood pressure medication regimen will be altered to initiate a thiazide-type or loop diuretic in those not already prescribed a diuretic, or to increase the dose if one is already prescribed.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Chronic Kidney Disease (CKD) include diuretics, ACE inhibitors, angiotensin receptor blockers (ARBs), and calcium channel blockers. Diuretics increase urine production to remove excess fluid, reducing volume overload and the risk of cardiovascular complications.
ACE inhibitors and ARBs relax blood vessels and lower blood pressure, decreasing the workload on the kidneys and slowing disease progression. Calcium channel blockers also lower blood pressure by relaxing blood vessels.
These treatments are essential for managing symptoms, preventing complications, and slowing the progression of CKD.
Kidney and aetiology, pathology and management of essential hypertension.Effectiveness, nephrotoxicity, and therapeutic drug monitoring of polymyxin B in nosocomial pneumonia among critically ill patients.Caloric restriction, physical exercise, and CB1 receptor blockade as an efficient combined strategy for bodyweight control and cardiometabolic status improvement in male rats.
Kidney and aetiology, pathology and management of essential hypertension.Effectiveness, nephrotoxicity, and therapeutic drug monitoring of polymyxin B in nosocomial pneumonia among critically ill patients.Caloric restriction, physical exercise, and CB1 receptor blockade as an efficient combined strategy for bodyweight control and cardiometabolic status improvement in male rats.
Find a Location
Who is running the clinical trial?
VA Office of Research and DevelopmentLead Sponsor
1,658 Previous Clinical Trials
3,361,602 Total Patients Enrolled
Lucile P Gregg, MDPrincipal InvestigatorMichael E. DeBakey VA Medical Center, Houston, TX
1 Previous Clinical Trials
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am able to understand and give informed consent.My kidney function is very low (stage 4-5 CKD).I have been diagnosed with liver cirrhosis.Your blood potassium level is less than 3.5 mEq/L before starting the study.I am willing and able to follow the study's requirements.I have received a kidney transplant.Your blood pressure was too high at your last two doctor visits.Your heart's pumping ability is less than 40%, as seen in your echocardiogram.I am a Veteran aged 18 or older.I have been diagnosed with mild to moderate kidney disease for at least 3 months.I am on long-term dialysis treatment.I have had a major limb amputation.You have a pacemaker or defibrillator.
Research Study Groups:
This trial has the following groups:- Group 1: Diuretic augmentation
Share this study with friends
Copy Link
Messenger